Stock listing

M55 Stock Price, News, Filings & Events — Macrogenics, Inc.

Selected listing: M55 · HAM · EUR · DE

This page tracks Macrogenics, Inc.'s M55:HAM listing on HAM in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following M55:HAM. M55:HAM is the stock-level entry point for investors researching Macrogenics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Macrogenics, Inc. (ticker: MGNX) is a public company based in America with a market capitalization of approximately $235.2 million. The company focuses on developing innovative therapies for cancer and other serious diseases. Macrogenics aims to advance its pipeline of biologic therapies to improve patient outcomes.

M55:HAMEURDEUpdated September 11, 2026
Macrogenics, Inc. logo
Ticker
M55:HAM
Asset type
Stock
Market cap
$254.8M
Sector
Health Technology
Industry
Pharmaceuticals: Major
Exchange
HAM
Currency
EUR

Macrogenics, Inc. M55:HAM stock context

This page tracks Macrogenics, Inc.'s M55:HAM listing on HAM in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following M55:HAM. M55:HAM is the stock-level entry point for investors researching Macrogenics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Macrogenics, Inc. (ticker: MGNX) is a public company based in America with a market capitalization of approximately $235.2 million. The company focuses on developing innovative therapies for cancer and other serious diseases. Macrogenics aims to advance its pipeline of biologic therapies to improve patient outcomes.

Latest news from Macrogenics, Inc.

All Macrogenics, Inc. news →

Macrogenics, Inc. earnings calls

Research Macrogenics, Inc.

Alternate listings